Skip to main content

Johnson & Johnson CFO on Q2 earnings beat

Johnson & Johnson CFO, breaks down the company's quarterly numbers which beat on the top and bottom line, helped by improved cancer drug sales.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.